[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571943":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":10,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"NEOMIX-WP3 cohort",null,"NEOMIX-WP3 cohort corresponds to the patients incluses in the ARMED NEO cohort (NICU patients) between February 2018 And June 2019. These children are now between 6 And 7. Their parents will be asked by validated questionnaries to evaluate the Neurodevelopmental status And eventual risk factors since they got back home after NICU stay",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Lise Laclautre","CONTACT","0473754963","promo_interne_drci@chu-clermontferrand.fr",[19,36],{"facility":20,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"CHU Clermont-Ferrand","Clermont-Ferrand","France","FR",{"type":25,"coordinates":26},"Point",[27,28],3.08682,45.77969,{"lat":28,"lon":27},[31,33],{"name":14,"role":15,"phone":32,"phoneExt":10,"email":17},"04.73.75.49.63",{"name":34,"role":35,"phone":10,"phoneExt":10,"email":10},"Catherine SARRET","PRINCIPAL_INVESTIGATOR",{"facility":37,"status":10,"city":38,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":39,"geoPoint":43,"contacts":44},"CHU de Lille","Lille",{"type":25,"coordinates":40},[41,42],3.05512,50.63391,{"lat":42,"lon":41},[45],{"name":46,"role":35,"phone":10,"phoneExt":10,"email":10},"Laurent STORME",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571943","neonatal-multiexposure-to-medical-devices-plasticizers-endocrine-disruption-mixture-effects-and-neurodevelopmental-disorders-100571943",false,"NCT06726824","NEOnatal Multiexposure to Medical Devices Plasticizers: Endocrine Disruption MIXture Effects and Neurodevelopmental Disorders","NEOMIX WP3","Inclusion Criteria:\n\n* Live patient who participated in the ARMED NEO study, included at the Clermont-Ferrand or Lille hospitals\n* Patient whose holders of parental authority have expressed their non-opposition to their participation in the study\n\nExclusion Criteria:\n\n* Patient whose guardians have expressed opposition to their participation in the study\n* Patient with no French speaking parent\n* patient",true,"ALL",{"count":59,"type":60},97,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the neurodevelopment of children from the ARMED NEO cohort through the ASQ3 score.\n\nDose the multiexposure to medical devices plasticizers during the neonatal intensive care unit stay increases the risk of developing neurodevelopmental disorders ? Patients (their parents) will complète several questionnaires (ASQ3, environnemental survey, EPICES score) during a planned teleconsultation with the research team",[64],"Neurodevelopmental Disorder (Diagnosis)",[66,67,68,69,70],"Neurodevelopmental disorder","Multiexposure","Medical devices","Plasticizers","Cocktail effects","NOT_YET_RECRUITING","2024-12-06",{"date":74,"type":75},"2024-12-10","ACTUAL",{"date":77,"type":60},"2024-12",{"date":79,"type":60},"2025-12",{"name":5,"class":6},2]